WO2009072625A1 - ヘテロ環化合物による造血幹細胞の増幅方法 - Google Patents
ヘテロ環化合物による造血幹細胞の増幅方法 Download PDFInfo
- Publication number
- WO2009072625A1 WO2009072625A1 PCT/JP2008/072189 JP2008072189W WO2009072625A1 WO 2009072625 A1 WO2009072625 A1 WO 2009072625A1 JP 2008072189 W JP2008072189 W JP 2008072189W WO 2009072625 A1 WO2009072625 A1 WO 2009072625A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- positive cells
- hematopoietic stem
- stem cells
- amplification method
- heterocyclic compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009544753A JP5573160B2 (ja) | 2007-12-05 | 2008-12-05 | ヘテロ環化合物による造血幹細胞の増幅方法 |
EP08857879A EP2228434A4 (en) | 2007-12-05 | 2008-12-05 | Amplification method for hematopoietic stem cells with heterocyclic compound |
US12/746,433 US20100310535A1 (en) | 2007-12-05 | 2008-12-05 | Method for expanding hematopoietic stem cells using heterocyclic compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007315167 | 2007-12-05 | ||
JP2007-315167 | 2007-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009072625A1 true WO2009072625A1 (ja) | 2009-06-11 |
Family
ID=40717803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/072189 WO2009072625A1 (ja) | 2007-12-05 | 2008-12-05 | ヘテロ環化合物による造血幹細胞の増幅方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100310535A1 (ja) |
EP (1) | EP2228434A4 (ja) |
JP (1) | JP5573160B2 (ja) |
WO (1) | WO2009072625A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2009072626A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
JPWO2009072624A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
WO2013051625A1 (ja) | 2011-10-03 | 2013-04-11 | 日産化学工業株式会社 | 多能性幹細胞からの巨核球及び/又は血小板の製造方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
US20220249567A1 (en) * | 2019-07-22 | 2022-08-11 | Glycostem Therapeutics B.V. | Low density cell culture |
WO2022020210A1 (en) | 2020-07-18 | 2022-01-27 | Ossium Health, Inc. | Permeation of whole vertebral bodies with a cryoprotectant using vacuum assisted diffusion |
AU2021360590A1 (en) | 2020-10-14 | 2023-06-15 | Ossium Health, Inc. | Systems and methods for extraction and cryopreservation of bone marrow |
EP4262831A1 (en) | 2020-12-18 | 2023-10-25 | Ossium Health, Inc. | Methods of cell therapies |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002502617A (ja) | 1998-02-17 | 2002-01-29 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
JP2006506452A (ja) * | 2002-10-09 | 2006-02-23 | 日産化学工業株式会社 | ピラゾロン化合物及びトロンボポエチンレセプター活性化剤 |
JP2006061106A (ja) | 2004-08-27 | 2006-03-09 | Hiroo Iwata | 造血幹細胞の製造方法 |
WO2006062247A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換複素環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006062240A1 (en) | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
WO2006062249A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006064957A1 (ja) * | 2004-12-14 | 2006-06-22 | Nissan Chemical Industries, Ltd. | アミド化合物及びトロンボポエチンレセプター活性化剤 |
JP2006527187A (ja) * | 2003-06-06 | 2006-11-30 | 日産化学工業株式会社 | ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
WO2007052808A1 (ja) * | 2005-11-07 | 2007-05-10 | Nissan Chemical Industries, Ltd. | ヒドラジド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007142308A1 (ja) * | 2006-06-07 | 2007-12-13 | Nissan Chemical Industries, Ltd. | 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030044978A1 (en) * | 1998-02-05 | 2003-03-06 | Novartis Corporation | Expanded and genetically modified populations of human hematopoietic stem cells |
CA2318819A1 (en) * | 1998-02-05 | 1999-08-12 | Novartis Ag | Expanded and genetically modified populations of human hematopoietic stem cells |
EP1179049A2 (en) * | 1999-05-14 | 2002-02-13 | City of Hope | (ex vivo) expansion of mammalian hematopoietic stem cells |
JPWO2003014336A1 (ja) * | 2001-08-07 | 2004-11-25 | 麒麟麦酒株式会社 | 造血幹細胞の製造法 |
JP5573159B2 (ja) * | 2007-12-05 | 2014-08-20 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
EP2233561A4 (en) * | 2007-12-05 | 2013-01-16 | Nissan Chemical Ind Ltd | METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND |
-
2008
- 2008-12-05 EP EP08857879A patent/EP2228434A4/en not_active Withdrawn
- 2008-12-05 US US12/746,433 patent/US20100310535A1/en not_active Abandoned
- 2008-12-05 WO PCT/JP2008/072189 patent/WO2009072625A1/ja active Application Filing
- 2008-12-05 JP JP2009544753A patent/JP5573160B2/ja not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002502617A (ja) | 1998-02-17 | 2002-01-29 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
JP2006506452A (ja) * | 2002-10-09 | 2006-02-23 | 日産化学工業株式会社 | ピラゾロン化合物及びトロンボポエチンレセプター活性化剤 |
JP2006527187A (ja) * | 2003-06-06 | 2006-11-30 | 日産化学工業株式会社 | ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
JP2006061106A (ja) | 2004-08-27 | 2006-03-09 | Hiroo Iwata | 造血幹細胞の製造方法 |
WO2006062247A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換複素環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006062240A1 (en) | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
WO2006062249A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006064957A1 (ja) * | 2004-12-14 | 2006-06-22 | Nissan Chemical Industries, Ltd. | アミド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007052808A1 (ja) * | 2005-11-07 | 2007-05-10 | Nissan Chemical Industries, Ltd. | ヒドラジド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007142308A1 (ja) * | 2006-06-07 | 2007-12-13 | Nissan Chemical Industries, Ltd. | 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
Non-Patent Citations (19)
Title |
---|
CASSEL, A. ET AL., EXP. HEMATOL., vol. 21, 1993, pages 585 - 91 |
CHUTE, JP ET AL., PROC NATL ACAD SCI USA., vol. 103, 2006, pages 11707 - 12 |
CWIRLA, S.E. ET AL.: "Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine", SCIENCE, vol. 276, no. 5319, 1997, pages 1696 - 1699, XP008136351 * |
EMA, H. ET AL., BLOOD, vol. 75, 1990, pages 1941 - 6 |
ISHIZAWA, L. ET AL., J HEMATOTHER., vol. 2, 1993, pages 333 - 8 |
KAUSHANSKY, K ET AL., ANN NY ACAD SCI., vol. 1044, 2005, pages 139 - 141 |
KURTZBERT, J. ET AL., NEW ENG. J. MED., vol. 335, 1996, pages 157 - 66 |
LAM AC ET AL., TRANSFUSION., vol. 41, no. 12, December 2001 (2001-12-01), pages 1567 - 76 |
LEUNG, AY ET AL., EXP HEMATOL., vol. 33, 2005, pages 422 - 7 |
LIU, J. ET AL.: "Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow", BONE MARROW TRANSPLANT., vol. 24, no. 3, 1999, pages 247 - 252, XP008136342 * |
LU, L. ET AL., EXP. HEMATOL., vol. 11, 1983, pages 721 - 9 |
MILHEM, M ET AL., BLOOD, vol. 103, 2004, pages 4102 - 10 |
NAKAMURA, T. ET AL.: "A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis", BLOOD, vol. 107, no. 11, 2006, pages 4300 - 4307, XP008136356 * |
ORLIC, D ET AL., NATURE, vol. 410, 2001, pages 701 - 5 |
ROSLER, E ET AL., EXP HEMATOL., vol. 28, 2000, pages 841 - 52 |
See also references of EP2228434A4 * |
SHIMAKURA, Y. ET AL., STEM CELLS, vol. 18, 2000, pages 183 - 9 |
TAGUCHI, A ET AL., J CLIN INVEST., vol. 114, 2004, pages 330 - 8 |
TATEISHI-YUYAMA, E ET AL., LANCET, vol. 360, 2002, pages 427 - 35 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2009072626A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
JPWO2009072624A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
JP5573159B2 (ja) * | 2007-12-05 | 2014-08-20 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
JP5573161B2 (ja) * | 2007-12-05 | 2014-08-20 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
US9115341B2 (en) | 2007-12-05 | 2015-08-25 | Nissan Chemical Industries, Ltd. | Method for expanding hematopoietic stem cells using heterocyclic compound |
WO2013051625A1 (ja) | 2011-10-03 | 2013-04-11 | 日産化学工業株式会社 | 多能性幹細胞からの巨核球及び/又は血小板の製造方法 |
KR20140082673A (ko) | 2011-10-03 | 2014-07-02 | 닛산 가가쿠 고교 가부시키 가이샤 | 다능성 간세포로부터의 거핵구 및/또는 혈소판의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
US20100310535A1 (en) | 2010-12-09 |
JPWO2009072625A1 (ja) | 2011-04-28 |
EP2228434A1 (en) | 2010-09-15 |
JP5573160B2 (ja) | 2014-08-20 |
EP2228434A4 (en) | 2013-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009072625A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
WO2009072624A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
WO2009072626A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
WO2009072635A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
WO2007103550A3 (en) | Substituted aminothiazole derivatives with anti-hcv activity | |
NZ599342A (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
TN2009000249A1 (en) | Mapk/erk kinase inhibitors | |
MX2008013582A (es) | Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa. | |
WO2008116107A3 (en) | Piperazine derivatives as glucokinase activators | |
SG196855A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
TN2010000131A1 (en) | Polo-like kinase inhibitors | |
MX2009012595A (es) | Derivados de espiroindolinona. | |
MX356756B (es) | Células madre pluripotentes en microportadores. | |
WO2007104034A3 (en) | Glucokinase activators | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
PE20061073A1 (es) | Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas | |
WO2007143434A3 (en) | Indazole and isoindole derivatives as glucokinase activating agents | |
TW200611897A (en) | Organic compounds | |
TW200745137A (en) | Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | |
NZ579928A (en) | Fluorinated derivatives of deferiprone | |
WO2008115890A3 (en) | Mapk/erk kinase inhibitors | |
WO2008114812A1 (ja) | Jak阻害剤 | |
MX2012006696A (es) | Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina. | |
MX2010009276A (es) | Pirrolopirimidincarboxamidas. | |
EP2581442A4 (en) | PROCESS FOR PRODUCING HEMATOPOIETIC STEM CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08857879 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009544753 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2008857879 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008857879 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12746433 Country of ref document: US |